Xtant Medical

2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014

Xtant Medical Holdings, Inc. Announces Expiration of Rights Offering

06/19/18

BELGRADE, MT, June 19, 2018 (GLOBE NEWSWIRE) -- XtantTM Medical Holdings, Inc. (NYSE American: XTNT) announces that the subscription period for its previously announced rights offering (the “Offering”) of shares of the Company’s common stock at a s...

Read More

Xtant Medical Receives FDA 510(K) Clearance for InTice™-C Porous Titanium Cervical Interbody System

05/21/18

BELGRADE, MT / ACCESSWIRE / May 21, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, announces U.S. Food and Drug Administration (FDA) 510(k) clearance for I...

Read More

Xtant Medical Announces First Quarter 2018 Financial Results

05/08/18

BELGRADE, MT / ACCESSWIRE / May 8, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today reported financial and operating results for the first quarter of 2...

Read More

Xtant Medical to Issue First Quarter 2018 Results on May 8th, 2018

05/02/18

BELGRADE, MT / ACCESSWIRE / May 2, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the quarte...

Read More

Xtant Medical Enhances Focus on International Growth with New Partnership

04/18/18

BELGRADE, MT / ACCESSWIRE / April 18, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, announced that it has entered into an agreement with Healthcare Intern...

Read More

Xtant Medical Holdings, Inc. Announces Record Date for Proposed Rights Offering

04/17/18

BELGRADE, MT / ACCESSWIRE / April 17, 2018 / Xtant™ Medical Holdings, Inc. (NYSE American: XTNT) announced today that it has set April 27, 2018 as the record date for a proposed rights offering of its shares of common stock.At the commencement of the...

Read More

Xtant Announces Fourth Quarter and Year End 2017 Financial Results

04/02/18

BELGRADE, MT / ACCESSWIRE / April 2, 2018 / Xtant™ Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today reported its financial results for the period ended December 31s...

Read More

Xtant Medical to Issue Fourth Quarter and Full Year 2017 Financial Results Monday, April 2

03/27/18

BELGRADE, MT / ACCESSWIRE / March 27, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the fou...

Read More

Xtant Medical Announces Compliance with NYSE American

02/15/18

Reports Pro Forma Stockholders’ Equity of approximately $47.4M as of 2/15/18 Xtant has regained compliance with the NYSE American listing standards BELGRADE, Mont., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE America...

Read More

Xtant Medical Announces Exchange of Outstanding Convertible Notes and Closing of Private Placement

02/14/18

Exchange of $70.238M (plus interest) of convertible notes into 10,401,309 shares of common stock at $7.20 per share. $6.809M Private Placement representing 945,819 shares of common stock at $7.20 per share. BELGRADE, Mont., Feb. 14, 2018 (GLO...

Read More

Xtant Medical Announces Results of Special Meeting of Stockholders

02/13/18

Approval of the issuance of new shares of common stock, as required by the NYSE American. Approval of an amendment to its certificate of incorporation, enabling its previously announced 1:12 reverse stock split. Approval of new directors to...

Read More

Xtant Medical Enters into Restructuring and Exchange Agreement with All Holders of Outstanding Convertible Notes

01/18/18

Conversion of $1.627M (plus interest) of convertible notes into common stock Exchange of $70.238M (plus interest) of convertible notes into common stock Upon stockholder approval, amendment of Certificate of Incorporation to effect reverse st...

Read More